Valeant Pharmaceuticals
Article Abstract:
A comparative analysis of the company sales and earnings and the financial details of Valeant Pharmaceuticals from 1988 - 2003 are illustrated. Projections of the equity price of this company for 2004 - 2005 is made using Value Line estimates.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
Pharmaceutical preparations, Valeant Pharmaceuticals International
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Schering-Plough Corp
Article Abstract:
Schering-Plough Corp. faces difficulties this year one of which was caused by the loss of its patent for Claritin. Investors are advised to look elsewhere.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Forecasts, trends, outlooks, Financial management, Patents & copyrights, Labor Distribution by Employer, Finance, Company investment, Investments, Statistics, Intellectual property, Schering-Plough Corp., SGP, Company business forecast/projection, Company forecasts, Claritin (Medication)
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Pharmaceutical industry, Securities, Company sales and earnings, Company earnings/profit, Company securities
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.